| Title |
Publication Date |
Price |
Relevance |
GlaxoSmithKline: PharmaVitae Profile
PharmaVitae Profile
|
January 2007 |
£3000 |
100 % |
GlaxoSmithKline Plc - SWOT Analysis
|
October 2008 |
£66 |
35 % |
GlaxoSmithKline Plc - OTC Healthcare World
|
January 2008 |
£195 |
33.5 % |
Spotlight Report Series: Deal Making Spotlight on GlaxoSmithKline
|
April 2006 |
£350 |
26 % |
Spotlight Report Series: Deal Making Spotlight on Novartis
|
April 2006 |
£350 |
26 % |
Spotlight Report Series: Deal Making Spotlight on Johnson & Johnson
|
April 2006 |
£350 |
26 % |
Spotlight Report Series: Deal Making Spotlight on Pfizer
|
April 2006 |
£350 |
26 % |
Spotlight Report Series: Deal Making Spotlight on Sanofi-Aventis
|
April 2006 |
£350 |
26 % |
AstraZeneca PLC - SWOT Analysis
|
October 2008 |
£66 |
22.5 % |
Shionogi & Co Ltd Deals
Partneringdesk briefing
|
July 2005 |
£215 |
22 % |
Stakeholder Opinion: Erectile Dysfunction
Identifying product differentiation and patient segmentation strategies
|
December 2006 |
£2005 |
21 % |
Forecast Insight: Insomnia Orexin and serotonin receptor modulators to innovate market
|
August 2008 |
£7600 |
21 % |
Neurodegenerative Market Forecast to 2013
|
February 2009 |
£6100 |
21 % |
World Pharmaceutical Market (2007)
|
November 2006 |
£455 |
20.5 % |
Global Vaccine Market Outlook (2007-2010)
|
June 2007 |
£975 |
19 % |
Sanofi-aventis
Pipeline, Products,Performance,Potential
|
September 2007 |
£249 |
18.5 % |
GlaxoSmithKline plc: PharmaVitae Profile
|
March 2009 |
£3010 |
18.2 % |
Insulin Delivery Systems Market Analysis (2007-2010)
|
May 2007 |
£855 |
18 % |
GlaxoSmithKline Partnering Guide 2008
|
July 2008 |
£195 |
17.5 % |
The Top 50 Pharmaceutical Manufacturing Companies In Ireland
|
September 2005 |
£285 |
17 % |
Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape
|
August 2008 |
£3800 |
16.1 % |
The Top 100 In Vitro Diagnostics Manufacturing Companies In Europe
(2nd ed.)
|
April 2004 |
£595 |
14.5 % |
The Top 40 Manufacturers Of Orthopaedic Implants In Europe
|
May 2005 |
£240 |
14 % |
The Top 40 Manufacturers Of Wound Care Products In Europe
|
June 2009 |
£240 |
14 % |
The Top 100 Contract Research Organisations In Europe
|
April 2004 |
£595 |
14 % |
Analgesics in the United Kingdom
|
August 2006 |
£450 |
13.65 % |
Wound Treatments in the United Kingdom
|
August 2006 |
£450 |
13.65 % |
Eye Care in the United Kingdom
|
August 2006 |
£450 |
13.65 % |
The Top 40 Manufacturers Of Diagnostic Imaging Equipment In Europe
|
June 2009 |
£275 |
13.5 % |
NRT Smoking Cessation Aids in the United Kingdom
|
August 2006 |
£450 |
13.3 % |
NRT Smoking Cessation Aids in Argentina
|
June 2006 |
£450 |
13.3 % |
Vitamins and Dietary Supplements in the United Kingdom
|
August 2006 |
£450 |
12.95 % |
Medicated Skin Care in the United Kingdom
|
August 2006 |
£450 |
12.95 % |
Analgesics in Saudi Arabia
|
June 2006 |
£450 |
12.6 % |
The Top 35 Central Nervous System Drug Delivery Technology Companies Worldwide
|
May 2005 |
£245 |
12.5 % |
The Top 100 Point-Of-Care Manufacturing Companies Worldwide
Second Edition
|
May 2009 |
£595 |
12.5 % |
Cough, Cold and Allergy (Hay Fever) Remedies in the United Kingdom
|
August 2006 |
£450 |
12.25 % |
Digestive Remedies in Saudi Arabia
|
June 2006 |
£450 |
12.25 % |
Innovative And Targeted Cancer Therapies
Key Technologies, New Applications And Leading Players
|
July 2007 |
£1495 |
12.25 % |
Smoking Cessation Aids in Australia
|
February 2006 |
£450 |
12.25 % |
NRT Smoking Cessation Aids in Saudi Arabia
|
June 2006 |
£450 |
12.25 % |
The Top 50 Neurodevice Companies Worldwide
|
June 2009 |
£300 |
12 % |
Cardiovascular Pharmaceutical Market Trends, 2007 to 2010
Key market forecasts and growth opportunities
|
August 2007 |
£895 |
11.9 % |
Eye Care in United States
|
May 2006 |
£450 |
11.9 % |
Vitamins And Dietary Supplements in Saudi Arabia
|
June 2006 |
£450 |
11.9 % |
CNS Market Trends, 2007 to 2010
Key Market Forecasts and Growth Opportunities
|
June 2007 |
£995 |
11.9 % |
Digestive Remedies in United States
|
May 2006 |
£450 |
11.55 % |
NRT Smoking Cessation Aids in United States
|
May 2006 |
£450 |
11.55 % |
Medicated Skin Care in United States
|
May 2006 |
£450 |
11.55 % |
Mergers and Acquisitions in the Pharmaceuticals Sector, 2009
Critical success factors for competing in a consolidating market
|
April 2009 |
£1955 |
11.55 % |
Vitamins And Dietary Supplements in United States
|
May 2006 |
£450 |
11.55 % |
Pharmaceutical Market Trends, 2008 - 2012
Key market forecasts and growth opportunities (3rd Edition)
|
November 2008 |
£1350 |
11.2 % |
OTC in Cameroon
|
May 2006 |
£295 |
11.2 % |
OTC Healthcare in Kenya
|
August 2006 |
£450 |
10.85 % |
Cough, Cold And Allergy (Hay Fever) Remedies in United States
|
May 2006 |
£450 |
10.85 % |
Pharmaceutical Product Approval Trends, 2007
Key Market Benchmarks And Strategic Insights
|
December 2007 |
£995 |
10.15 % |
Celgene Corporation: PharmaVitae Profile
Healthcare
|
March 2009 |
£3010 |
9.8 % |
United States Pharmaceuticals and Healthcare Report Q3 2006
|
July 2006 |
£395 |
9.5 % |
Medicated Skin Care in Argentina
|
August 2007 |
£450 |
9.1 % |
Medicated Skin Care in Brazil
|
August 2007 |
£450 |
8.75 % |
Argentina Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
November 2008 |
£1830 |
8.75 % |
Mexico Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
November 2008 |
£1830 |
8.75 % |
Digestive Remedies in Brazil
|
August 2007 |
£450 |
8.4 % |
Digestive Remedies in China
|
September 2007 |
£450 |
8.4 % |
Republic of Korea Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
December 2008 |
£1830 |
8.4 % |
Medicated Skin Care in Venezuela
|
February 2008 |
£450 |
8.4 % |
Merck KGaA - OTC Healthcare - World
|
January 2008 |
£195 |
8.4 % |
Brazil Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2015
|
March 2009 |
£1525 |
8.05 % |
Digestive Remedies in Argentina
|
August 2007 |
£450 |
8.05 % |
Eye Care in Brazil
|
August 2007 |
£450 |
8.05 % |
Commercial Insight: HIV - The battle for market share is getting fiercer
|
August 2008 |
£7600 |
7.7 % |
Emerging Pharmaceutical Markets Globally
|
April 2008 |
£915 |
7.35 % |
Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry
|
January 2008 |
£650 |
7.35 % |
Japan Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1830 |
7.35 % |
Spain Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1830 |
7 % |
Global Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2015
|
March 2009 |
£2440 |
7 % |
Italy Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1830 |
7 % |
Bigpharma Dealmaking Handbook
Companies & Contacts
|
September 2008 |
£1195 |
7 % |
Belgium Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1830 |
7 % |
Zimbabwe Pharmaceuticals and Healthcare Report Q3 2008
|
September 2008 |
£425 |
7 % |
United States Drug Delivery Devices Medical Equipment Industry Report
Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Infusion Systems, Inhalation Systems and Needle Free Injections Medical Equipment and Supplies
|
April 2008 |
£1830 |
7 % |
Australia Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2015
|
March 2009 |
£1525 |
7 % |
Fastest Growing Biotechnology Companies, The
Growth Strategies, Comparative Analyses and Company Profiles
|
March 2008 |
£1995 |
7 % |
Netherlands Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1830 |
6.65 % |
Canada Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1830 |
6.65 % |
China Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1830 |
6.65 % |
France Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1830 |
6.65 % |
Germany Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1830 |
6.65 % |
Mexico Pharmaceuticals and Healthcare Report Q3 2008
|
July 2008 |
£425 |
6.65 % |
Bigpharma Dealmaking and Agreements Handbook 2007
Companies, Contacts & Partnering Agreements
|
September 2007 |
£1195 |
6.65 % |
South Africa Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1830 |
6.3 % |
UK Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1830 |
6.3 % |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£5960 |
6.3 % |
Clinical Trials Market in Russia
|
May 2009 |
£490 |
5.95 % |
Spain Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1830 |
5.95 % |
Pipeline/Commercial Insight: Supportive Care in Oncology
Significant growth opportunities exist in new supportive care indications
|
June 2007 |
£7600 |
5.6 % |
Therapeutic Peptides in Oncology
Favorable Conditions But Where to Commercialize?
|
May 2009 |
£2960 |
5.6 % |
China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1830 |
5.6 % |
The Global Antivirals Market
R&D Pipelines, Market Analysis and Competitive Landscape
|
May 2007 |
£1525 |
5.6 % |
Partnering with Biopharma
The definitive guide to bigpharma partnering interests, contacts & agreements
|
July 2008 |
£1495 |
5.6 % |
Analytical Tool - Current & Future Lung Cancer Therapeutics
|
May 2007 |
£2660 |
5.25 % |
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry
|
April 2009 |
£6000 |
5.25 % |
Commercial and Pipeline Insight
Vaccines for Adults and The Elderly - New Blockbuster Opportunities Ahead
|
July 2008 |
£7700 |
5.25 % |
United Sates Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2015
|
March 2009 |
£1525 |
5.25 % |
Commercial and Pipeline Insight
Vaccines for Adults and The Elderly - New Blockbuster Opportunities Ahead
|
July 2008 |
£7700 |
5.25 % |
Pharmaceutical Markets in India
|
April 2004 |
£790 |
4.9 % |
Pharmaceutical Markets in Brazil, Russia, India and China (Bric Nations)
|
July 2008 |
£1075 |
4.9 % |
The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023
|
May 2008 |
£1499 |
4.9 % |
United States Drug Delivery Devices Investment Opportunities
Analysis and Forecasts to 2012
|
September 2008 |
£1830 |
4.55 % |
Leukemia
A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking
|
April 2009 |
£1670 |
4.55 % |
Monoclonal Antibodies in Cancer Therapy 2009-2024
|
May 2009 |
£1499 |
4.55 % |
Stakeholder Opinions: Head and Neck Cancer
Innovatives to Change the Face of Treatment
|
November 2007 |
£2005 |
4.55 % |
Booming Clinical Trials Market in India
|
November 2007 |
£730 |
4.55 % |
CNS Drug Discoveries
What the Future Holds
|
November 2006 |
£1995 |
4.2 % |
Global Diabetes Market; The
Therapeutics, Diagnostics and Complications
|
August 2006 |
£1525 |
4.2 % |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
|
October 2006 |
£8000 |
4.2 % |
Pipeline and Commercial Insight: Anxiety Disorders Viable indication for antipsychotics companies
|
November 2008 |
£8000 |
4.2 % |
Pipeline Insight: Non-Small Cell Lung Cancer
Pipeline set to offer only modest improvements
|
April 2008 |
£6000 |
3.85 % |
Clinical Trials Market 2006, The
|
February 2006 |
£1499 |
3.85 % |
Stakeholder Insight: Chronic Leukemias
Is there room left for improvement?
|
November 2008 |
£8000 |
3.5 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
|
July 2007 |
£2365 |
3.5 % |
Top 10 Biotech Companies
Market Outlook, 2008-2023
|
December 2008 |
£1499 |
3.15 % |
Pipeline Insight: Molecular Targeted Cancer Therapies
More pipeline activity, less product differentiation
|
November 2008 |
£8000 |
3.15 % |
The Dermatology Market Outlook to 2013
Competitive Landscape, Pipeline Analysis and Growth Opportunities
|
October 2008 |
£2025 |
3.15 % |
The Vaccines 2008
World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry
|
April 2008 |
£2500 |
3.15 % |
China Pharma Outsourcing Market By 2015
|
January 2009 |
£1065 |
2.8 % |
World Gastrointestinal Disorders Market 2008-2023
|
October 2008 |
£1499 |
2.8 % |
Vaccines: The World Market
|
February 2007 |
£2435 |
2.8 % |
Vaccines
The World Market
|
February 2007 |
£2435 |
2.8 % |
Osteoporosis & Bone Metabolism Disorders Market
2008-2023
|
August 2008 |
£1499 |
2.8 % |
Pipeline and Commercial Insight: Nicotine Dependence - Chantix issues overshadow vaccine potential
Healthcare
|
March 2009 |
£8000 |
2.8 % |
Inflammatory Bowel Diseases
World Market Report 2009-2024
|
February 2009 |
£1499 |
2.45 % |
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
|
October 2006 |
£2960 |
2.45 % |
Therapeutic Monoclonal Antibodies Report 2008-2023
|
July 2008 |
£1499 |
2.45 % |
Low-Cost RFID Smart Labels
International Markets & Opportunities in Europe & North America
|
January 2007 |
£1715 |
2.45 % |
Stakeholder Opinions: Acute Leukemias
Persistent unmet needs confer significant commercial opportunity
|
April 2006 |
£2170 |
2.45 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
2.1 % |
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit
|
July 2007 |
£6000 |
1.75 % |
The Executive Guide to Molecular Imaging
|
July 2007 |
£595 |
1.75 % |
Companion Biomarkers in Drug Development
|
April 2009 |
£2075 |
1.05 % |
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008
|
May 2007 |
£260 |
1.05 % |
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2008/2009
|
June 2008 |
£260 |
1.05 % |
